Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, describes the ongoing SUNMO Phase III trial which is evaluating the efficacy and safety of mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (NHL) in comparison with the standard of care regimen rituximab, gemcitabine and oxaliplatin (R-GemOx) (NCT05171647). Dr Westin anticipates encouraging results from the novel targeted therapy being trialed in comparison to R-GemOx. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
